The path for prescription drugs to get approved and introduced on the market here in the United States is a multi-level process. Its manufacturer must generally get the preliminary go-ahead from the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) before they can move forward with the critical testing stage. Some drugs get fast-tracked though thus bypassing stringent analysis of it though.
The U.S. Food and Drug Administration (FDA) issued a recall of a popularly prescribed weight loss medication last week. The federal agency did so after discovering that lorcaserin, a drug that is more commonly known by its brand name Belviq, may put patients who take it at a higher risk for developing cancer.
TDF, or tenofovir disoproxil fumarate, is a drug designed to treat human immunodeficiency virus (HIV). Marketed by Gilead under the brand name Truvada (along with others), TDF drugs were seen as a first-line treatment for HIV.
Tenofovir disoproxil fumarite (TDF) drugs designed to treat the Human Immunodeficiency Virus (HIV) are marketed under a variety of names, including Truvada, Atripla, Viread. They've been a longstanding component of successful HIV treatment for many years for many people afflicted with this potentially deadly disease.
The U.S. Food and Drug Administration (FDA) issued a public warning to those who take the over-the-counter heartburn drug Zantac on Sept. 13. They announced that the same carcinogen that identified in prescription blood pressure medications earlier this year was also found in Zantac pills.
One of the U.S. Food and Drug Administration's (FDA) responsibilities is to inspect domestic or foreign facilities that manufacture drugs distributed to pharmacies and stores here in this country. This is supposed to keep defective or contaminated drugs from ending up in consumers' hands. The significant amount of warnings, recalls and pharmaceutical injury lawsuits that have been filed in recent years shows that this must not be an effective approach though.
The U.S. Food and Drug Administration (FDA) issued a recall of additional lots of the blood pressure medication Losartan on March 15. In announcing the voluntary recall, federal regulators and Legacy Pharmaceuticals Packaging, LLC, the drug's manufacturer, said that it may have been contaminated by a cancer-causing chemical.
The drug manufacturer Tris-Pharma issued a recall of additional batches of infants' ibuprofen drops this past week. This marks the second over-the-counter pain reliever recall that has been issued by this company since November.
Pharmaceutical research and the prescription of medications for what ails a patient is big business in the United States. Each year millions of Americans suffering from a variety of conditions are prescribed drugs to treat what ails them. While they help many of them recover from an illness or manage a chronic health condition, you may wonder what role your pharmacy plays it getting you information about unsafe medications.
A study published in the American Journal of Health-System Pharmacy in February of 2016 shed some light on some interesting on why medications and drugs get recalled by the Food and Drug Administration (FDA).